INCA033989 therapy to watch for CALR+ MPN patients

INCA033989 is a new drug that targets the CALR mutation in patients with MPNs (especially ET and MF). Something to keep an eye on, especially if you are a younger patient and concerned about being on hydroxyurea for more than 20 years.

The drug works by targeting only mutated cells and does not suppress other blood cells across the board like hydroxyurea can. According to info by the manufacturer, Incyte, INCA033989 is well tolerated and returns overall blood production to more normal levels:
https://investor.incyte.com/news-releases/news-release-details/positive-late-breaking-data-incytes-first-class-mutcalr-targeted/
Info right now info is short on short-term side effects for INCA033989. Long-term side effects won't be known for many years.

It is also likely that INCA033989 will be very expensive if/when it is released for general use. Jakafi, another Incyte drug, still runs thousands of dollars per month, though what patients pay is largely determined by insurance coverage.

Anyone have more info on this?